Benzodiazepines for schizophrenia.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.cd006391PMID 17253592
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Valproate for schizophrenia.

  2016cited by this paper
• Electroconvulsive therapy for schizophrenia.

  2005cited by this paper
• Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting

  2004cited by this paper
• Effect of minor and major tranquilizers on somatosensory evoked potentials

  2004cited by this paper
• Prophylactic effect of neuroleptics in symptom-free schizophrenics

  2004cited by this paper
• A double-blind outpatient study of diazepam (Valium) and placebo

  2004cited by this paper
• High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Lithium for schizophrenia.

  2003cited by this paper
• Prehospital thrombolysis

  2003cited by this paper
• Carbamazepine for schizophrenia and schizoaffective psychoses.

  2002cited by this paper
• Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis.

  2001cited by this paper
• Beta-blocker supplementation of standard drug treatment for schizophrenia.

  2001cited by this paper
• Dropout rates in randomised antipsychotic drug trials

  2001cited by this paper
• Unpublished rating scales: A major source of bias in randomised controlled trials of treatments for schizophrenia

  2000cited by this paper
• Clozapine versus typical neuroleptic medication for schizophrenia.

  2000cited by this paper
• Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study

  1999cited by this paper
• Diazepam treatment of early signs of exacerbation in schizophrenia.

  1999cited by this paper
• Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

  1999cited by this paper
• Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.

  1999cited by this paper
• Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol.

  1998cited by this paper
• Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting

  1997cited by this paper
• Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study.

  1997cited by this paper
• Trials randomised in clusters

  1997cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Improving the quality of reporting of randomized controlled trials. The CONSORT statement.

  1996cited by this paper
• Statistics Notes: Detecting skewness from summary information

  1996cited by this paper
• Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

  1995cited by this paper
• A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia.

  1994cited by this paper
• Beneficial effect of high-dose clotiazepam on intractable auditory hallucinations in chronic schizophrenic patients

  1994cited by this paper
• Placebo Response in Refractory Tardive Akathisia

  1993cited by this paper
• Usefulness of Antiparkinsonian Drugs during Neuroleptic Treatment and the Effect of Clonazepam on Akathisia and Parkinsonism Occurred after Antiparkinsonian Drug Withdrawal: A Double‐Blind Study

  1992cited by this paper
• Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia.

  1992cited by this paper
• The unit of analysis error in studies about physicians’ patient care behavior

  1992cited by this paper
• Haloperidol and Lorazepam Combined: Clinical Effects and Drug Plasma Levels in the Treatmentof Acute Schizophrenic Psychosis

  1992cited by this paper
• When symptoms persist: choosing among alternative somatic treatments for schizophrenia.

  1991cited by this paper
• Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior.

  1991cited by this paper
• The use of midazolam in acutely agitated psychiatric patients.

  1990cited by this paper
• Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.

  1990cited by this paper
• Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation.

  1989cited by this paper
• Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia.

  1989cited by this paper
• Development of a scale for assessment of agitation following traumatic brain injury.

  1989cited by this paper
• Successful Clonazepam Treatment of Neuroleptic‐Induced Akathisia in Older Adolescents and Young Adults: A Double‐Blind, Placebo‐Controlled Study

  1989cited by this paper
• Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.

  1988cited by this paper
• Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.

  1988cited by this paper
• Rapid tranquilization: antipsychotics or benzodiazepines?

  1988cited by this paper
• Lorazepam treatment of psychogenic catatonia: an update.

  1988cited by this paper
• The effect of benzodiazepines on tardive dyskinesia symptoms.

  1988cited by this paper
• Adjunctive benzodiazepines in acute schizophrenia.

  1987cited by this paper
• Treatment of catatonia with low-dose lorazepam.

  1987cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Clonazepam/haloperidol combination therapy in schizophrenia: A double blind study

  1987cited by this paper
• Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.

  1986cited by this paper
• Behavioral Side Effects of Triazolam in Psychiatric Inpatients: Report of Five Cases

  1986cited by this paper
• Efficacy of propranolol in neuroleptic-induced akathesia.

  1985cited by this paper
• Acute Effects of the Synthetic Analogue of Methionine Enkephalin FK 33-824 In Schizophrenic Patients

  1984cited by this paper
• Diazepam in Tardive Dyskinesia

  1983cited by this paper
• Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study.

  1982cited by this paper
• Diazepam in schizophrenia: a preliminary double-blind trial.

  1982cited by this paper
• Analgesic and euphoric effects of high dose diazepam in schizophrenia.

  1982cited by this paper
• Diazepam in high doses is effective in schizophrenia

  1982cited by this paper
• Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial.

  1982cited by this paper
• Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?

  1981cited by this paper
• Clonazepam and phenobarbital in tardive dyskinesia.

  1981cited by this paper
• Acute high-dose parenteral haloperidol treatment of psychosis.

  1979cited by this paper
• Benzodiazepines in chronic schizophrenia.

  1979cited by this paper
• A controlled long‐term study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects

  1978cited by this paper
• Clinical trial with a new substance (PLP 100-127) in order to asses therapeutic efficacy and dependence creating properties.

  1975cited by this paper
• Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive design study.

  1975cited by this paper
• Effects of control techniques on therapeutic outcome in a controlled clinical trial.

  1975cited by this paper
• [A new tranquilizer: lorazepam (158 cases)].

  1973cited by this paper
• SCH-12,041, a new anti-anxiety agent (quantitative pharmaco-electroencephalography and clinical trials).

  1972cited by this paper
• A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

  1970cited by this paper
• Weight changes with schizophrenic psychosis and psychotropic drug therapy.

  1970cited by this paper
• Laboratory Changes with Chlordiazepoxide and Thioridazine, Alone and Combined *

  1969cited by this paper
• Combined drug treatment of newly hospitalized, acutely ill psychiatric patients.

  1969cited by this paper
• Itil TM, Keskiner A, Fink M: Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia.

  1968cited by this paper
• A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients.

  1967cited by this paper
• Chlordiazepoxide in the treatment of patients with "activated EEG's".

  1967cited by this paper
• Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients.

  1966cited by this paper
• A comparative study with benzodiazepines in chronic psychotic patients.

  1966cited by this paper
• THE NURSES' OBSERVATION SCALE FOR INPATIENT EVALUATION: A NEW SCALE FOR MEASURING IMPROVEMENT IN CHRONIC SCHIZOPHRENIA.

  1965cited by this paper
• COMPARISON OF DIAZEPAM, CHLORPROTHIXENE AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC PATIENTS.

  1964cited by this paper
• Evidence of ten psychotic syndromes.

  1962cited by this paper
• A reference study of ataraxics. A two-week double blind outpatient evaluation.

  1962cited by this paper
• The Effects of Chlordiazepoxide (Librium) in Anxiety States: A Multi-Blind Study

  1962cited by this paper
• A revision of the psychiatric rating scale.

  1947cited by this paper

• Lack of Efficacy of Simvastatin Adjunctive Therapy for Patients with Schizophrenia: A Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia.

  2024cites this paper
• Prevalence and risk factors for misuse of prescription psychotropic drug in patients with severe mental illness: A systematic review

  2023cites this paper
• Prescription Pattern of Antipsychotics Polypharmacy in patients with Schizophrenia in an Indian Hospital

  2021cites this paper
• Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development.

  2020cites this paper
• Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: A review of the literature.

  2019cites this paper
• Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia

  2019cites this paper
• A Durable Minimal Intervention Strategy to Reduce Benzodiazepine Use in a Primary Care Population

  2019cites this paper
• Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey.

  2019cites this paper
• Complex Polypharmacy in Patients With Schizophrenia-Spectrum Disorders Before a Psychiatric Hospitalization: Prescribing Patterns and Associated Clinical Features

  2018cites this paper
• TREATMENT WITH PREGABALIN BY OLE SCHJERNING

  2018cites this paper
• GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia

  2018cites this paper
• Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States.

  2018cites this paper
• Concurrent benzodiazepine use in older adults treated with antidepressants in Asia

  2017cites this paper
• Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966

  2017cites this paper
• Chronic diazepam administration increases the expression of Lcn2 in the CNS

  2017cites this paper
• Benzodiazepines for psychosis-induced aggression or agitation.

  2017cites this paper
• Risk factors associated with benzodiazepine use among people who inject drugs in an urban Canadian setting.

  2016cites this paper
• Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders

  2016cites this paper
• Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial

  2016cites this paper
• Antipsychotic-like effects of zolpidem in Wistar rats.

  2016cites this paper
• Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use.

  2016cites this paper
• Re-examining the role of benzodiazepines in the treatment of schizophrenia: A systematic review

  2015cites this paper
• New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways

  2014cites this paper
• Differences Between Patients With Schizophrenia With and Without Co-Occurring Methamphetamine Use Disorders in a Taiwanese Public Psychiatric Hospital

  2014cites this paper
• The need to determine the best options for people with schizophrenia that is unresponsive to treatment.

  2013cites this paper
• Benzodiazepines for psychosis-induced aggression or agitation.

  2013cites this paper
• A Sensitive Period for GABAergic Interneurons in the Dentate Gyrus in Modulating Sensorimotor Gating

  2013cites this paper
• Role of Melatonin in Schizophrenia

  2013cites this paper
• Do Benzodiazepines Still Deserve a Major Role in The Treatment of Psychiatric Disorders? A Critical Reappraisal

  2013cites this paper
• Visual Surround Suppression in Schizophrenia

  2013cites this paper
• Polypharmacy for schizophrenia

  2013cites this paper
• Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment.

  2013cites this paper
• Benzodiazepines for schizophrenia.

  2012cites this paper
• Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.

  2012cites this paper
• Reduced Crowding and Poor Contour Detection in Schizophrenia Are Consistent with Weak Surround Inhibition

  2012cites this paper
• Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.

  2012cites this paper
• Prescription patterns of patients diagnosed with schizophrenia in mental hospitals in Tashkent/Uzbekistan and in four German cities

  2012cites this paper
• Development of disease-modifying treatment of schizophrenia.

  2012cites this paper
• Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.

  2012cites this paper
• Event sequencing of forced intramuscular medication in England.

  2012cites this paper
• Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008.

  2011cites this paper
• Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol

  2011cites this paper
• Using the needs of WHO to prioritise Cochrane reviews: The case of antipsychotic drugs

  2011cites this paper
• Concomitant medication of psychoses in a lifetime perspective

  2011cites this paper
• Carbon dioxide induction of panic anxiety in schizophrenia with auditory hallucinations.

  2011cites this paper
• Evidence-based pharmacotherapy of schizophrenia.

  2011cites this paper
• Benzodiazepine use among patients with schizophrenia in Taiwan: a nationwide population-based survey.

  2011cites this paper
• How Psychotropic Polypharmacy in Schizophrenia Begins: A Longitudinal Perspective

  2011cites this paper
• Benzodiazepine prescription among patients with severe mental illness and co‐occurring alcohol abuse/dependence in Taiwan

  2011cites this paper
• Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

  2010cites this paper
• Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future.

  2010cites this paper
• PRACTICAL DOSING STRATEGIES IN THE TREATMENT OF SCHIZOPHRENIA

  2010cites this paper
• Atypical behavioural effects of lorazepam: clues to the design of novel therapies?

  2010cites this paper
• Chlorpromazine for psychosis induced aggression or agitation.

  2010cites this paper
• Combination Therapy in the Treatment of Schizophrenia

  2010cites this paper
• Are antipsychotics antipsychotics?

  2010cites this paper
• Augmentation of atypical antipsychotics with valproic acid. An open‐label study for most difficult patients with schizophrenia

  2009cites this paper
• A critique of the dopamine hypothesis of schizophrenia and psychosis.

  2009cites this paper
• Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023.

  2009cites this paper
• [Therapeutic alliance, a stake in schizophrenia].

  2009cites this paper
• Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.

  2009cites this paper
• The therapeutic value of antipsychotic drugs : A critical analysis of cochrane meta-analyses of the therapeutic value of anti-psychotic drugs used in Denmark

  2009cites this paper
• Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

  2009cites this paper
• Second meeting of the French CEIP (Centres d'Evaluation et d'Information sur la Pharmacodépendance). Part II: benzodiazepine withdrawal.

  2009cites this paper
• Antipsychotic Drug Treatment for Patients with Schizophrenia: Theoretical Background, Clinical Considerations and Patient Preferences

  2009cites this paper
• MISE AU POINT L ’ alliance thérapeutique , un enjeu dans la schizophrénie Therapeutic alliance , a stake in schizophrenia

  2009cites this paper
• Benzodiazepine dependence: focus on withdrawal syndrome.

  2009cites this paper
• GABAB Receptors, Schizophrenia and Sleep Dysfunction

  2009cites this paper
• Intramuscular Aripiprazole

  2008cites this paper
• Valproate for schizophrenia.

  2008cites this paper
• The impact of a good practice manual on professional practice associated with psychotropic PRN in acute mental health wards: an exploratory study.

  2008cites this paper
• Unanswered questions in schizophrenia clinical trials.

  2007cites this paper
• Lithium for schizophrenia.

  2007cites this paper
• The role of cortical inhibition in the pathophysiology and treatment of schizophrenia.

  2007cites this paper
• Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine

  2007cites this paper